Charles Duncan
Stock Analyst at Cantor Fitzgerald
(1.47)
# 1425
Out of 5,225 analysts
304
Total ratings
36.67%
Success rate
16.06%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ITCI Intra-Cellular Thera... | Reiterates: Neutral | 132 132 | n/a | n/a | 22 | Apr 2, 2025 | |
CMPS Compass Pathways | Reiterates: Overweight | n/a | n/a | n/a | 6 | Mar 28, 2025 | |
ACAD ACADIA Pharmaceutica... | Reiterates: Overweight | 28 28 | 14.82 | 88.93% | 21 | Feb 27, 2025 | |
JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | 140 150 | 109.1 | 37.49% | 6 | Feb 26, 2025 | |
AXSM Axsome Therapeutics | Reiterates: Overweight | 153 153 | 105.38 | 45.19% | 22 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 14 | 9.5 | 47.37% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 17 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 7 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 4 4 | n/a | n/a | 9 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 51 58 | 29.46 | 96.88% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 43 | 27.7 | 55.23% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 155 155 | 105.82 | 46.48% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 35 35 | 15.51 | 125.66% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 13 | 4.33 | 200.23% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 34 34 | 23.2 | 46.55% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 330 330 | n/a | n/a | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 38 45 | n/a | n/a | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 52 50 | 33.38 | 49.79% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 5 | 3.67 | 36.24% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 7 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 4 | 0.36 | 1011.11% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 4 | 1.33 | 200.75% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 58 | 38.23 | 51.71% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 10 | n/a | n/a | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 110 | 0.9 | 12122.22% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 80 | 3.17 | 2423.66% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 172 | n/a | n/a | 12 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 3 | 1.07 | 180.37% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 11 | 9.46 | 16.28% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 9 12 | 5.69 | 110.9% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 146 168 | 7.05 | 2282.98% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 5 | n/a | n/a | 4 | Apr 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 2.32 | 762.07% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 200 | 22.52 | 788.1% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 52 | n/a | n/a | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 8 4 | 0.34 | 1076.47% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 24 | 1.66 | 1345.78% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 372 144 | 1.92 | 7400% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 26 | n/a | n/a | 1 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 24 35 | n/a | n/a | 3 | Sep 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 3 4 | 1.41 | 183.69% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 1224 1440 | 5.32 | 26967.67% | 4 | May 19, 2020 |